Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 8/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.48 |
| ▸ | PLK1 | P53350 | 5/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.45 |
| ▸ | SMO | Q99835 | 3/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932871 | 0.88 | KDR (0.48) | KDRPTK2PLK1AURKBMEN1 | |
| SCHEMBL9932908 | 0.88 | KDR (0.48) | ACHEKDRPTK2PLK1AURKB | |
| SCHEMBL9932137 | 0.82 | LMNA (0.51) | KDRPTK2PLK1AURKBPIK3CD | |
| SCHEMBL9932520 | 0.82 | MEN1 (0.48) | KDRPTK2MEN1KMT2APIK3CD | |
| SCHEMBL9971186 | 0.80 | SMO (0.48) | ACHEMEN1KMT2APIK3CDPIK3R1 | |
| SCHEMBL9931835 | 0.80 | SMO (0.61) | ACHEMEN1KMT2APIK3CDPIK3R1 | |
| SCHEMBL9932291 | 0.79 | MEN1 (0.48) | MEN1KMT2ASMONCF1 | |
| SCHEMBL9932455 | 0.76 | ITGB2 (0.49) | MEN1KMT2ASMONCF1 | |
| SCHEMBL9932108 | 0.76 | SMO (0.63) | KDRPTK2PLK1AURKBAKT1 | |
| SCHEMBL13033515 | 0.74 | SMO (0.58) | MEN1KMT2ASMONCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | ACHE 2961/4885KDR 1623/4885PTK2 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.